Close Menu

NEW YORK – ArcherDx and AstraZeneca have formed a strategic collaboration to develop assays to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer, the companies said on Tuesday.

Under the terms of the agreement, Boulder, Colorado-based ArcherDx will perform exome sequencing of resected non-small cell lung cancer patient samples and generate patient-specific, research-use-only circulating tumor DNA assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.